Business
Nkarta to Participate in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on
About this update from Nkarta, Inc.
[{"type":"image","alt":"Nkarta, Inc.","displaySize":"","headline":null,"caption":"Nkarta, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E3HnIhM4alJb8N_ScZ3_Cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0","width":300,"height":78}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month:","length":276,"tagName":"p"},{"type":"text","content":"Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat","length":81,"tagName":"p"},{"type":"text","content":"TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat","length":91,"tagName":"p"},{"type":"text","content":"A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.","length":189,"tagName":"p"},{"type":"text","content":"About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.","length":576,"tagName":"p"},{"type":"text","content":"Nkarta Media/Investor Contact:Nadir MahmoodNkarta, [email protected]","length":79,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]